535 results on '"Defer, Gilles"'
Search Results
2. Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
3. Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
4. Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
5. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
6. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
7. Influence des inégalités socio-territoriales sur la mortalité en excès de patients atteints de SEP en France : une étude rétrospective observationnelle
8. Syndrome inflammatoire de reconstitution immune précédant l’administration du deuxième cycle de cladribine chez une SEP-RR
9. Résultats de l’étude d’extension NOVA évaluant la préférence des patients pour l’administration sous-cutanée (SC) versus intraveineuse (IV) de natalizumab (NTZ) avec le schéma Q6W (toutes les 6 semaines)
10. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
11. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
12. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference
13. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.
14. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society
15. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis
16. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
17. Psychological interventions in multiple sclerosis: Improving cognition and quality of life
18. Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality
19. Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
20. Relapses During High-Dose Biotin Treatment in Progressive Multiple Sclerosis: a Case-Crossover and Propensity Score-Adjusted Prospective Cohort
21. Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?
22. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
23. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
24. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.
25. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study
26. Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin
27. Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trial
28. Historique de la sclérose en plaques
29. Immunologie de la sclérose en plaques
30. Épidémiologie, environnement et génétique dans la sclérose en plaques
31. Histoire naturelle de la sclérose en plaques
32. Sécurité des essais cliniques : accompagnement de l’investigateur par le vigilant pour la publication des données de sécurité. Une ligne directrice du groupe REVISE
33. Dementia in Multiple Sclerosis
34. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: a retrospective observational cohort study
35. Influence of education on cognitive performance and dopamine transporter binding in dementia with Lewy bodies
36. The radiologically isolated syndrome: revised diagnostic criteria
37. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study
38. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
39. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
40. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system
41. Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis
42. Transverse Myelitis Following SARS‐CoV‐2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database
43. 136 NOVA primary results randomised controlled study of natalizumab Q6W versus continued Q4W treatment for MS
44. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
45. No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans
46. Préface
47. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial
48. Fatigue is associated with metabolic and density alterations of cortical and deep gray matter in Relapsing-Remitting-Multiple Sclerosis patients at the earlier stage of the disease: A PET/MR study
49. Primary Results of NOVA: a Randomized Controlled Study of the Efficacy of 6 - Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (S14.005)
50. Résultats primaires de NOVA : une étude contrôlée randomisée comparant l’administration de natalizumab toutes les 6 semaines versus une administration continue toutes les 4 semaines dans le traitement de la sclérose en plaques
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.